March 2008 in “Aging health” This research reported that docetaxel is generally safe and effective for elderly patients with solid tumor malignancies, showing no significant age-related differences in efficacy or toxicity.
March 2018 in “International journal of basic and clinical pharmacology” This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.
December 2023 in “Frontiers in oncology” The study found that patients over 70 with advanced ovarian cancer may have better overall and progression-free survival with weekly paclitaxel-carboplatin chemotherapy compared to a three-weekly regimen, despite increased blood-related toxicities.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
September 2019 in “Pakistan Journal of Pharmaceutical Sciences” This study found that combining pemetrexed with platinum drugs led to better treatment outcomes and fewer adverse reactions in elderly patients with advanced lung adenocarcinoma compared to pemetrexed alone.